

## EXHIBIT 19

**From:** Trent Tanner <ttanner@hilgersgraben.com>  
**Sent:** Tuesday, November 10, 2020 6:50 PM  
**To:** Nisbet, Brian; Tsukerman, Lev  
**Cc:** Wickramasekera, Nimalka; Alphatec Service; WSGR - NUVA/A TEC; NuVa-HG  
**Subject:** RE: NuVasive v. Alphatec - Tanner letter to Nisbet

Brian –

At this time, NuVasive has no further information to provide in response to Alphatec's interrogatories regarding the first sale, use, etc., of the embodying implants. As NuVasive's witnesses have made clear in recent depositions, any and all individuals with personal knowledge regarding NuVasive's sales of embodying products before March 29, 2004 are no longer with NuVasive. Therefore, NuVasive has no corporate knowledge of these issues beyond the documents we have already produced and pointed you to pursuant to FRCP 33(d).

Trent Tanner  
Hilgers Graben PLLC  
Direct: (402) 260-1391  
Cell: (480) 334-7296

---

**From:** Nisbet, Brian <BNisbet@winston.com>  
**Sent:** Tuesday, November 10, 2020 2:40 PM  
**To:** Tsukerman, Lev <LTsukerman@winston.com>; Trent Tanner <ttanner@hilgersgraben.com>  
**Cc:** Wickramasekera, Nimalka <NWickramasekera@winston.com>; Alphatec Service <AlphatecService@winston.com>; WSGR - NUVA/A TEC <nuva/atec@wsgr.com>; NuVa-HG <NuVa-HG@hilgersgraben.com>  
**Subject:** RE: NuVasive v. Alphatec - Tanner letter to Nisbet

**\*\*External Email - Do not open suspicious attachments or links from known or unknown senders.\*\***

Trent,

Following up on our call last week concerning the outstanding issue in our discovery deficiency letter, as discussed, please provide a formal supplement to your interrogatory response containing an affirmative statement confirming the use and sale of the embodying Cement Restrictor XL and CoRoent XL prior to March 29, 2004, in light of the deposition Friday and counsel's emails conceding that very thing.

Thanks,

Brian

---

**From:** Nisbet, Brian  
**Sent:** Monday, November 2, 2020 3:34 PM  
**To:** Tsukerman, Lev <LTsukerman@winston.com>; Trent Tanner <ttanner@hilgersgraben.com>  
**Cc:** Wickramasekera, Nimalka <NWickramasekera@winston.com>; Alphatec Service <AlphatecService@winston.com>; WSGR - NUVA/A TEC <nuva/atec@wsgr.com>; NuVa-HG <NuVa-HG@hilgersgraben.com>  
**Subject:** RE: NuVasive v. Alphatec - Tanner letter to Nisbet

Please advise when we can expect a response to our letter.

Thanks,

Brian

---

**From:** Tsukerman, Lev <[LTsukerman@winston.com](mailto:LTsukerman@winston.com)>

**Sent:** Tuesday, October 27, 2020 11:16 PM

**To:** Trent Tanner <[ttanner@hilgersgraben.com](mailto:ttanner@hilgersgraben.com)>; Nisbet, Brian <[BNisbet@winston.com](mailto:BNisbet@winston.com)>

**Cc:** Wickramasekera, Nimalka <[NWickramasekera@winston.com](mailto:NWickramasekera@winston.com)>; Alphatec Service <[AlphatecService@winston.com](mailto:AlphatecService@winston.com)>;

WSGR - NUVA/A TEC <[nuva/atec@wsgr.com](mailto:nuva/atec@wsgr.com)>; NuVa-HG <[NuVa-HG@hilgersgraben.com](mailto:NuVa-HG@hilgersgraben.com)>

**Subject:** RE: NuVasive v. Alphatec - Tanner letter to Nisbet

Trent,

Please see attached.

Best,

Lev

**Lev Tsukerman**

Associate Attorney

Winston & Strawn LLP

T: +1 213-615-1700

D: +1 213-615-1834

[winston.com](http://winston.com)



---

**From:** Trent Tanner <[ttanner@hilgersgraben.com](mailto:ttanner@hilgersgraben.com)>

**Sent:** Monday, October 12, 2020 12:16 PM

**To:** Nisbet, Brian <[BNisbet@winston.com](mailto:BNisbet@winston.com)>

**Cc:** Wickramasekera, Nimalka <[NWickramasekera@winston.com](mailto:NWickramasekera@winston.com)>; Alphatec Service <[AlphatecService@winston.com](mailto:AlphatecService@winston.com)>;

WSGR - NUVA/A TEC <[nuva/atec@wsgr.com](mailto:nuva/atec@wsgr.com)>; NuVa-HG <[NuVa-HG@hilgersgraben.com](mailto:NuVa-HG@hilgersgraben.com)>

**Subject:** NuVasive v. Alphatec - Tanner letter to Nisbet

Brian –

Please see attached. Thanks.

Trent Tanner

HILGERS GRABEN PLLC

[www.hilgersgraben.com](http://www.hilgersgraben.com)

Lincoln | Omaha | Denver | Dallas | Atlanta

(402) 260-1391 (direct) | (480) 334-7296 (cell)

[Bio](#) | [LinkedIn](#)

The contents of this message may be privileged and confidential. If this message has been received in error, please delete it without reading it. Your receipt of this message is not intended to waive any applicable privilege. Please do not disseminate this message without the permission of the author. Any tax advice contained in this email was not intended to be used, and cannot be used, by you (or any other taxpayer) to avoid penalties under applicable tax laws and regulations.